Nov. 8, 2012 | Vol. 11 No. 220 | Full Issue in PDF Format
View the entire issue.
A 10-member FDA advisory panel voted unanimously Wednesday to recommend approval of Novartis’ Signifor for the treatment of Cushing’s disease.
Hospira continues to remain at risk for a consent decree as negative manufacturing updates, additional form 483 observations and product recalls pile up, one analyst says.
The DOJ is looking into Novartis’ relationship with Accredo Health Group, handing the specialty pharmacy company a subpoena on dealings related to iron overload drug Exjade.
The FDA has denied Public Citizen’s appeal for a ban on the 23-mg dose of Eisai’s Alzheimer’s drug Aricept.
Massachusetts’ public health commissioner has fired the director of the state’s Board of Registration in Pharmacy (MBRP) for overlooking an early complaint about the compounding pharmacy now linked to a meningitis outbreak.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.